{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:02:23Z","timestamp":1792544543950,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007319","name":"Albert Einstein College of Medicine","doi-asserted-by":"publisher","award":["T32 GM007288"],"award-info":[{"award-number":["T32 GM007288"]}],"id":[{"id":"10.13039\/100007319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.jaad.2019.09.071","type":"journal-article","created":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T11:03:55Z","timestamp":1570187035000},"page":"1094-1101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"title":["High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa"],"prefix":"10.1016","volume":"82","author":[{"given":"Mondana H.","family":"Ghias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison J.","family":"Kutner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Micheletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Dean","family":"Hosgood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2019.09.071_bib1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2217\/imt-2018-0090","article-title":"Biologics for hidradenitis suppurativa: an update","volume":"11","author":"Wlodarek","year":"2019","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jaad.2019.09.071_bib2","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2019.09.071_bib3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations. Part II: topical, intralesional, and systemic medical management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.09.071_bib4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaad.2009.06.050","article-title":"Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial","volume":"62","author":"Grant","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.09.071_bib5","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3109\/09546634.2011.571657","article-title":"Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa","volume":"23","author":"van Rappard","year":"2012","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2019.09.071_bib6","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jaad.2019.05.022","article-title":"Determining the optimal dose of infliximab for treatment of hidradenitis suppurativa","volume":"81","author":"Oskardmay","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.09.071_bib7","doi-asserted-by":"crossref","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","article-title":"Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial","volume":"157","author":"Kimball","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2019.09.071_bib8","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/j.1365-2133.2011.10254.x","article-title":"Elevated levels of tumour necrosis factor (TNF)-alpha, interleukin (IL)-1beta and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-alpha and IL-1beta","volume":"164","author":"van der Zee","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.09.071_bib9","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00403-015-1596-5","article-title":"Patients with hidradenitis suppurativa carry a higher systemic inflammatory load than other dermatological patients","volume":"307","author":"Riis","year":"2015","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaad.2019.09.071_bib10","series-title":"Infliximab [package insert]","year":"2017"},{"key":"10.1016\/j.jaad.2019.09.071_bib11","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/bjd.12713","article-title":"Four-weekly infliximab in the treatment of severe hidradenitis suppurativa","volume":"170","author":"Moriarty","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.09.071_bib12","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1046\/j.1365-2036.2001.00956.x","article-title":"Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease","volume":"15","author":"Cornillie","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jaad.2019.09.071_bib13","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S1526-5900(03)00716-8","article-title":"Interpretation of visual analog scale ratings and change scores: a reanalysis of two clinical trials of postoperative pain","volume":"4","author":"Jensen","year":"2003","journal-title":"J Pain"},{"key":"10.1016\/j.jaad.2019.09.071_bib14","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1111\/jdv.15353","article-title":"Evaluation of medical and surgical treatments for hidradenitis suppurativa using real-life data from the Scandinavian registry (HISREG)","volume":"33","author":"Grimstad","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2019.09.071_bib15","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0885-3924(03)00162-3","article-title":"Clinically important changes in acute pain outcome measures: a validation study","volume":"25","author":"Farrar","year":"2003","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.jaad.2019.09.071_bib16","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000431175","article-title":"Hidradenitis suppurativa\/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation","volume":"231","author":"Zouboulis","year":"2015","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2019.09.071_bib17","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","article-title":"European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa","volume":"29","author":"Zouboulis","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2019.09.071_bib18","series-title":"R: A Language and Environment for Statistical Computing","year":"2018"},{"key":"10.1016\/j.jaad.2019.09.071_bib19","first-page":"469","article-title":"Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions","volume":"23","author":"Edrees","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaad.2019.09.071_bib20","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/art.10302","article-title":"The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial","volume":"46","author":"St Clair","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2019.09.071_bib21","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1080\/03009740701416758","article-title":"Infliximab dosage and infusion frequency in clinical practice: experiences in the Stockholm biologics registry STURE","volume":"36","author":"van Vollenhoven","year":"2007","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.jaad.2019.09.071_bib22","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/ibd.21886","article-title":"Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn's disease","volume":"18","author":"Hibi","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jaad.2019.09.071_bib23","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jaad.2013.10.059","article-title":"Long-term durability and dose escalation patterns in infliximab therapy for psoriasis","volume":"70","author":"Luber","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.09.071_bib24","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1097\/MIB.0000000000000212","article-title":"Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study","volume":"20","author":"Dotan","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jaad.2019.09.071_bib25","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1097\/MPG.0000000000001034","article-title":"Durability of infliximab is associated with disease extent in children with inflammatory bowel disease","volume":"62","author":"Shapiro","year":"2016","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jaad.2019.09.071_bib26","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1053\/j.gastro.2009.06.061","article-title":"Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab","volume":"137","author":"Sandborn","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaad.2019.09.071_bib27","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/j.1468-3083.2011.04065.x","article-title":"Obesity and psoriasis: body weight and body mass index influence the response to biological treatment","volume":"25","author":"Puig","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2019.09.071_bib28","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/dth.12364","article-title":"Clinical predictors of nonresponse to anti-TNF-alpha agents in psoriatic patients: a retrospective study","volume":"29","author":"De Simone","year":"2016","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2019.09.071_bib29","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/bjd.12422","article-title":"Survival rate of antitumour necrosis factor-alpha treatments for psoriasis in routine dermatological practice: a multicentre observational study","volume":"169","author":"Esposito","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.09.071_bib30","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/j.1365-2133.2011.10213.x","article-title":"Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris","volume":"164","author":"Gniadecki","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.09.071_bib31","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/rheumatology\/kel149","article-title":"Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register","volume":"45","author":"Hyrich","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2019.09.071_bib32","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1007\/s00296-011-2033-5","article-title":"Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational study","volume":"32","author":"Kleinert","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jaad.2019.09.071_bib33","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1196\/annals.1351.019","article-title":"Epidemiological aspects of rheumatoid arthritis: the sex ratio","volume":"1069","author":"Kvien","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jaad.2019.09.071_bib34","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/ajg.2012.218","article-title":"Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jaad.2019.09.071_bib35","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jaad.2016.12.015","article-title":"Disease modification for hidradenitis suppurativa: a new paradigm","volume":"76","author":"Paek","year":"2017","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219328208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219328208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:53:25Z","timestamp":1759272805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962219328208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0190962219328208"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2019.09.071","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2019.09.071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}